Efficacy of cyclin-dependent kinase 4/6 inhibitors in patients with metastatic hormone positive breast cancer: a single institutional study from India

26 Sep 2022
Sandip Ganguly, Navonil Mukherjee, Sayan Mandal, Somnath Roy, Sanjit Agarwal, Bivas Biswas, Joydeep Ghosh

Purpose: Cyclin-dependent kinase 4/6 (CDK4/6) inhibitors have shown marked benefit in the treatment of hormone positive metastatic breast cancer (HR+ MBC). There are limited real-world studies with palbociclib and ribociclib. Here we report our experience with CDK4/6 inhibitors in these groups of patients.

Material and methods: Patients with HR+ MBC who have received either palbociclib or ribociclib during the course of their treatment from January 2017 to January 2022 were included in the study. The baseline demographic features, treatment details and toxicity were recorded. Patients who received at least 1 month of therapy were included in the survival analysis.

Results: A total of 144 patients received CDK4/6 inhibitors during the time period. The median age of the population was 53 (30–80) years. Ninety-eight (71.4%) patients presented with de novo metastatic disease. The most common site of metastasis was to the skeleton (74.2%). Most patients (75%) received palbociclib as their therapy. At a median follow-up of 20.2 months, the median progression free survival (PFS) of the whole population was 16.5 (95% confidence interval (95% CI): 11.6–25.5) months and the median overall survival (OS) was 29.7 (95% CI: 21.7–44.6) months. The presence of liver metastases, low progesterone receptor positivity (Allred score < 6) and prior systemic treatment were poor prognostic factors for both PFS and OS in multivariate analysis. Drug was discontinued for only 2.1% of the patient population.

Conclusions: Use of CDK4/6 inhibitors has led to improvement in PFS and OS in patients with HR+ MBC and it is well tolerated. The presence of liver metastases and low progesterone receptor positivity (Allred score < 6) and prior treatment are poor prognostic factors.

Related Articles

Anjana Vinod, Ishika Mahajan, Aruni Ghose, Saraswathy Sreeram
Tabassum Wadasadawala, Anup Akanksha, Johnny Carlton, Rajiv Sarin, Sudeep Gupta, Vani Parmar, Rima Pathak, Jaya Ghosh, Jyoti Bajpai, Seema Gulia, Revathy Krishnamurthy
Shridevi Subramaniam, Yek-Ching Kong, Cheng-Har Yip, Muthukkumaran Thiagarajan, Jayalakshmi Pailoor, Hafizah Zaharah, Nur Aishah Taib, Mee-Hoong See, Diana Sarfati, Nirmala Bhoo-Pathy
Pablo Aldaz-Roldán, Diego F Pardo-Vásquez, Geanella N Chamba-Morales, Daniel F Aguirre-Reyes, Johana M Castillo-Calvas, Gabriela Noblecilla-Arévalo
Funmilola Wuraola, Olalekan Olasehinde, Matteo Di Bernardo, Patrick Akinyemi, Israel Owoade, Tajudeen Mohammed, Adewale Aderounmu, Samson Ogunleye, Adeoluwa Adeleye, Mary Ogunyemi, Gregory Knapp, Peter Kingham, Olusegun Alatise